

Original Article

Static first-minute-frame (FMF) PET imaging after ^{18}F -labeled amyloid tracer injection is correlated to [^{18}F]FDG PET in patients with primary progressive aphasia

Adolfo Gómez-Grande^{a,b,*,1}, Alexander P. Seiffert^{c,*,1}, Alberto Villarejo-Galende^{b,d,e,f}, Marta González-Sánchez^{d,e,f}, Sara Llamas-Velasco^{d,e,f}, Héctor Bueno^{b,g,h,i}, Enrique J. Gómez^{c,j}, María José Tabuenca^a, Patricia Sánchez-González^{c,j}

^a Department of Nuclear Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

^b Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain

^c Biomedical Engineering and Telemedicine Centre, ETSI Telecomunicación, Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain

^d Department of Neurology, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain

^e Group of Neurodegenerative Diseases, Hospital 12 de Octubre Research Institute (imas12), 28041 Madrid, Spain

^f Biomedical Research Networking Center in Neurodegenerative Diseases (CIBERNED), 28029 Madrid, Spain

^g Department of Cardiology and Instituto de Investigación Sanitaria (imas12), 28041 Hospital Universitario 12 de Octubre, Madrid, Spain

^h Centro Nacional de Investigaciones Cardiovasculares (CNIC), 28029 Madrid, Spain

ⁱ Centro de Investigación Biomédica en Red de enfermedades Cardiovasculares (CIBERCV), 28029 Madrid, Spain

^j Centro de Investigación Biomédica en Red de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, 28029 Madrid, Spain

ARTICLE INFO

Article history:

Received 27 July 2022

Accepted 6 October 2022

Available online 7 February 2023

Keywords:

First-minute-frame

Amyloid PET

Early-phase

Primary progressive aphasia

Neurodegeneration biomarker

ABSTRACT

Objective: To study the correlation between a static PET image of the first-minute-frame (FMF) acquired with ^{18}F -labeled amyloid-binding radiotracers and brain [^{18}F]FDG PET in patients with primary progressive aphasia (PPA).

Material and methods: The study cohort includes 17 patients diagnosed with PPA with the following distribution: 9 nonfluent variant PPA, 4 logopenic variant PPA, 1 semantic variant PPA, 3 unclassifiable PPA. Regional SUVRs are extracted from FMFs and their corresponding [^{18}F]FDG PET images and Pearson's correlation coefficients are calculated.

Results: SUVRs of both images show similar patterns of regional cerebral alterations. Inpatient correlation analyses result in a mean coefficient of $r = 0.94 \pm 0.06$. Regional interpatient correlation coefficients of the study cohort are greater than 0.81. Radiotracer-specific and variant-specific subcohorts show no difference in the similarity between the images.

Conclusions: The static FMF could be a valid alternative to dynamic early-phase amyloid PET proposed in the literature, and a neurodegeneration biomarker for the diagnosis and classification of PPA in amyloid PET studies.

© 2023 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Medicina Nuclear e Imagen Molecular. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Una imagen PET amiloide estática del primer minuto (FMF) se correlaciona con [^{18}F]FDG PET en pacientes con afasia progresiva primaria

RESUMEN

Objetivo: Estudiar la correlación entre una imagen PET estática del primer minuto (FMF) adquirida con radiotrazadores de amiloide marcados con flúor-18 y la [^{18}F]FDG PET cerebral en pacientes con afasia primaria progresiva (APP).

Material y métodos: La cohorte de estudio incluye 17 pacientes diagnosticados de APP con la siguiente distribución: 9 APP variante no fluente, 4 APP variante logopénica, 1 APP variante semántica, 3 APP inclasificable. Se extraen los SUVR regionales de las FMF y sus correspondientes imágenes [^{18}F]FDG PET y se calculan los coeficientes de correlación de Pearson.

Palabras clave:

Imagen del primer minuto

PET amiloide

Fase precoz

Afasia primaria progresiva

Biomarcador de neuro-degeneración

* Corresponding authors.

E-mail addresses: adolfo.gomez@salud.madrid.org (A. Gómez-Grande), ap.seiffert@upm.es (A.P. Seiffert).

¹ Adolfo Gómez-Grande and Alexander P. Seiffert are joint first authors.

Resultados: Los SUVR de ambas imágenes muestran patrones similares de alteraciones cerebrales regionales. Los análisis de correlación intrapaciente dan como resultado un coeficiente medio de $r = 0,94 \pm 0,06$. Los coeficientes de correlación regional entre pacientes de la cohorte de estudio son superiores a 0,81. Las subcohortes específicas de radiotrazadores y variantes no muestran diferencias en la similitud entre las imágenes.

Conclusiones: La FMF estática podría ser una alternativa válida a la PET dinámica de fase temprana de amiloide propuesta en la literatura, y un biomarcador de neurodegeneración para el diagnóstico y la clasificación de la APP en los estudios de PET amiloide.

© 2023 El Autor(s). Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Medicina Nuclear e Imagen Molecular. Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Primary progressive aphasia (PPA) is a neurological syndrome characterized by the partial or total impairment of language-related functions due to neurodegenerative processes^{1,2}. It is a heterogeneous syndrome, with different neuropathological causes, and the specific speech and language features define the diagnosis and classification into the non-fluent/agrammatic variant (nfvPPA), semantic variant (svPPA), and logopenic variant (lvPPA)³. Regarding the underlying neuropathologies, nfvPPA is most often related to tau-positive or TDP-43-positive frontotemporal lobar degeneration (FTLD), svPPA to FTLD-TDP, and lvPPA is commonly an atypical presentation of Alzheimer's disease (AD)^{3,4}.

Due to the region-specific alterations of the cerebral metabolism in this syndrome and the underlying neuropathologies, both neurodegeneration image biomarkers ($[^{18}\text{F}]$ fluorodeoxyglucose PET, FDG) and imaging biomarkers of the pathophysiological processes (amyloid and tau PET) play an important role in the diagnosis and classification^{5–8}. Regarding the patterns of hypometabolism, nfvPPA has been shown to present frontal alterations, svPPA in the anterior temporal region, and lvPPA in the temporal-parietal region^{4,5,9–11}.

Early-phase amyloid PET images acquired with an amyloid-binding radiotracer like $[^{18}\text{F}]$ florbetapir (FBP), $[^{18}\text{F}]$ flutemetamol (FMM) or $[^{18}\text{F}]$ florbetaben (FBB) have shown their similarity to $[^{18}\text{F}]$ FDG PET^{12–20}. Moreover, the dual-phase protocol allows obtaining both information of neurodegeneration and amyloid load, which may also support the differential diagnosis of PPA variants⁶. While its main application has been studied for the diagnosis of AD, the use of early-phase amyloid PET images of patients with frontotemporal dementia (FTD)¹⁴ or PPA²¹ has also been evaluated.

In a previous study, we presented the first-minute-frame (FMF) of amyloid PET, a static perfusion-like image acquired during one minute after the injection of a ^{18}F -labeled amyloid-binding radiotracer²². The similarity to the gold standard in clinical routine practice, $[^{18}\text{F}]$ FDG PET, was demonstrated quantitatively showing high correlation coefficients. The advantage of the proposed image is the use of a common time window of the early-phase image with three ^{18}F -labeled amyloid-binding radiotracers, and of a static acquisition protocol, which facilitates the interpretation by nuclear medicine specialists in clinical routine practice. In this study, the comparability of the FMF and $[^{18}\text{F}]$ FDG PET is evaluated specifically in a study cohort of patients with PPA.

Material and methods

Patients

The initial retrospectively selected database consisted of a cohort of patients with available dual-phase amyloid and $[^{18}\text{F}]$ FDG PET images acquired between February 2016 and July 2019 in the Department of Nuclear Medicine of the Hospital Universitario 12

de Octubre, Madrid, Spain. Patients without a diagnosis of PPA were excluded. PPA classification was performed prior to $[^{18}\text{F}]$ FDG PET imaging according to neuropsychological assessment, structural neuroimaging, and clinical judgement by neurologists and neuropsychologists based on the diagnostic criteria defined by Gorno-Tempini et al.³. Those patients who did not meet the criteria of nfvPPA, lvPPA or svPPA were defined as unclassified (ucPPA).

PET imaging

FMF imaging

FMFs were acquired using $[^{18}\text{F}]$ FBP or $[^{18}\text{F}]$ FMM on a Siemens Biograph 6 True Point PET/CT scanner (Siemens Healthcare, Erlangen, Germany). Images were acquired after the intravenous injection of radiotracer doses of 410 ± 13 MBq and 193 ± 17 MBq, respectively. Static image acquisition with a duration of 1 min was performed for a total of 10 min immediately post injection (p.i.) and the FMF was recorded. Images were reconstructed using a point spread function (PSF) reconstruction algorithm (3 iterations, 21 subsets, all-pass filter) and they were corrected for attenuation with a low-dose CT scan and scatter and random correction were also performed. The reconstructed images had a matrix size of 168×168 and voxel size of $4.0728 \times 4.0728 \times 5$ mm³.

$[^{18}\text{F}]$ FDG PET imaging

$[^{18}\text{F}]$ FDG PET scans were acquired on a Siemens Biograph 6 True Point PET/CT scanner (Siemens Healthcare, Erlangen, Germany). A $[^{18}\text{F}]$ FDG dose of 275 ± 103 MBq was intravenously injected, and PET images were recorded 30–68 min p.i. The images were reconstructed with a PSF algorithm (6 iterations, 16 subsets; Gaussian filter: 3 mm). A low-dose CT scan was used for attenuation correction and random and scatter correction were performed. The reconstructed images had a matrix size of 336×336 and voxel size of $1.0182 \times 1.0812 \times 3$ mm³.

Image analysis

Statistical Parametric Mapping 12 (SPM12) (Wellcome Centre for Human Neuroimaging, University College London, London United Kingdom)²³ was used for the preprocessing of all images. To account for anatomical interpatient differences, the unified segmentation algorithm of SPM12 is employed to spatially normalize the images to the standard space defined by the Montreal Neurological Institute (MNI). The CT images corresponding to either the amyloid PET/CT or $[^{18}\text{F}]$ FDG PET/CT acquisition protocols were used as anatomical reference as described by Presotto et al.²⁴. Resulting images have a matrix size of $91 \times 109 \times 91$ and voxel size of $2 \times 2 \times 2$ mm³. Then, a total of 68 cortical and subcortical brain regions are segmented with the Automatic Anatomical Labelling (AAL2) atlas^{25,26}. With 68 of these regions, 8 volumes of interest (VOI) are defined that correspond to the frontal, occipital, parietal and temporal lobes, the anterior and posterior cortices (ACC and PCC, respectively), the precuneus, and the striatum. Regional radio-

tracer uptake is quantified calculating standardized uptake value ratios (SUVr) using the grey matter part of the cerebellum.

Statistical analysis

Quantitative variables are represented as mean $\pm$ standard deviation (SD). The normality of distributions was studied using the Shapiro–Wilk test. Regional SUVr from FMFs and [^{18}F]FDG images of the study cohort, as well as for radiotracer-specific and PPA variant-specific subcohorts, were compared calculating two-way mixed average measure intraclass correlation coefficients (r) and paired t -tests or Wilcoxon's signed rank test. Due to the small study cohort of 17 patients, correlations for amyloid state-specific subcohorts, and dividing the PPA-specific subcohorts by radiotracer, were not calculated. For group analyses, the single available case with svPPA is grouped with the ucPPA cases as 'Other PPA'. All statistical analyses are performed in MATLAB R2019a (The Math-Works, Inc., Natick, MA, USA) and SPSS software version 26.00 (IBM Corp., Armonk, NY, USA), and p -values <0.05 are considered statistically significant.

Results

Demographics and image data

A total of 17 patients (age 68.41 ± 7.56 years, female: 8) with available FMF and [^{18}F]FDG PET scans were included in the retrospective study cohort. Dual-phase amyloid PET imaging was performed 48.72 ± 50.71 days after [^{18}F]FDG PET/CT acquisition. All patients were diagnosed with suspected PPA. The study cohort comprised 9 patients with nvPPA, 4 with lvPPA, 1 with svPPA and 3 with ucPPA. Amyloid PET positivity by visual analysis was 2/9 (22.22%) for nvPPA, 4/4 (100%) for lvPPA, 0/1 (0.00%) for svPPA, and 3/3 (100%) for ucPPA. Table 1 summarizes the demographics of the study cohort.

Examples of FMFs and their corresponding [^{18}F]FDG PET images are shown in Fig. 1. Comparing the FMF to the [^{18}F]FDG PET scan, a similar pattern of perfusion/metabolism can be observed in both images, with the same cortical regions showing reduced activity.

SUVr analysis

Regional SUVr of FMFs and their corresponding [^{18}F]FDG PET images are summarized in Table 2. Higher regional SUVr can be observed in the [^{18}F]FDG PET images but the trends of regional low/high remain the same in both images. Overall, the lowest values in all radiotracer-specific subcohorts can be seen in the striatum, and the lowest cortical values in the temporal region. On the other hand, due to the visual activity of the patient during image acquisition, the occipital region shows the highest SUVr.

Table 3 shows the regional SUVr for variant-specific subcohorts. Again, FMFs and [^{18}F]FDG PET show similar regional SUVr but are overall slightly higher in the second image. Reduced temporal metabolism can be observed in all groups. Additionally, SUVr are more reduced in the ACC in the nvPPA group than in the other two.

Correlation analyses

First, the inpatient correlations between regional SUVr of FMFs and their corresponding [^{18}F]FDG PET images is obtained, resulting in a mean correlation of $r = 0.95 \pm 0.04$. When dividing by radiotracer, the mean inpatient correlation coefficients are $r = 0.94 \pm 0.05$ and $r = 0.97 \pm 0.02$ for [^{18}F]FBP and [^{18}F]FMM, respectively. Regarding variant-specific subgroups, the mean intra-

patient correlations are $r = \pm 0.03$ (nvPPA), $r = 0.93 \pm 0.07$ (lvPPA), and $r = 0.97 \pm 0.02$ (Other PPA).

Regional interpatient correlation coefficients between SUVr of FMFs and their corresponding [^{18}F]FDG PET images are summarised in Table 4. Strong significant positive correlations >0.84 are obtained in all regions for the study cohort. The same occurs for the radiotracer-specific subcohorts. When dividing by PPA variant, the overall best results are obtained in the nvPPA subcohort. However, strong positive correlations, albeit not always statistically significant, can also be seen in the other two PPA variant-specific subcohorts. Representative correlation charts of the frontal, parietal, and temporal regions for the whole study cohort are shown in Fig. 2.

Discussion

The FMF is a simple-to-acquire perfusion-like image that allows obtaining information about neurodegeneration and A β deposition (with the late-phase A β PET image) in the same session. In this study, the similarity of the FMF to the clinical gold standard for neurodegeneration [^{18}F]FDG PET is evaluated in a cohort of patients with PPA. In previous studies, early-phase amyloid PET images were acquired during multiple minutes, having to select radiotracer-specific time windows either during acquisition or when reconstructing dynamic data acquired in list mode^{12,19}. The FMF, in contrast, is an alternative that is more widely available and with a common time window for the three ^{18}F -labeled amyloid-binding PET radiotracers.

As seen in the SUVr analyses, [^{18}F]FDG PET images present overall higher values than FMFs, but the offset is consistent and statistically significant across all regions. This same pattern is seen in previous

studies evaluating early-phase amyloid PET images acquired with [^{18}F]FBP^{12–15} and [^{18}F]FBB^{19,20}. Moreover, regional SUVr alterations are also consistent within subcohorts. When dividing by PPA variant, SUVr also follow patterns which are consistent with those described in the literature^{3–5,9}. However, no statistically significant differences were found between the 'nvPPA' and 'lvPPA' groups (the 'Other PPA' group was excluded in this analysis due to its heterogeneous composition).

Regarding correlation analyses, inpatient analyses show very high r values. These are also comparable or higher than the within-subject correlation coefficients obtained by Hsiao et al.¹² and Asghar et al.¹⁴, both using [^{18}F]FBP and time windows of 0–2 and 2–5 min, respectively. The similarity between the images as shown by the inpatient analyses is also independent of the used radiotracer and the variant of the PPA where strong correlations are obtained.

Regional interpatient correlation coefficients are slightly lower than inpatient values, while still being strong among the regions in the study cohort ($r = 0.92 \pm 0.03$). With some exceptions, regional interpatient correlation coefficients are similarly high in both radiotracer-specific and variant-specific subcohorts. The lowest regional correlation coefficients are obtained in the right frontal region ($r = 0.20$, 'lvPPA' subcohort) and the ACC ($r = 0.59$, $r = 0.70$ or $r = 0.73$ in the 'Other PPA', [^{18}F]FBP, 'lvPPA' subcohorts, respectively), which, while not usually affected in AD but being a relatively small region, may be considered altered by artifacts due to patient movement during the acquisition. In addition, it has been shown to present reduced metabolism in [^{18}F]FDG PET and be affected by atrophy^{27–29}. While still strong, some regional correlation coefficients are also statistically non-significant, which may be explained by the low number of patients once the study cohort is divided by PPA variant. In comparison to previous studies, regional correlation coefficients are comparable or higher^{12,13,15–20}, even though

Table 1
Study cohort demographics.

	N	Age, years (mean $\pm$ SD)	Sex (m/f)	Amyloid state ($\pm$)	nvPPA	lvPPA	svPPA	ucPPA
All patients	17	68.41 $\pm$ 7.56	9/8	9/8	9	4	1	3
FMF with [18 F]FBP	11	69.82 $\pm$ 5.42	7/4	7/4	5	3	1	2
FMF with [18 F]FMM	6	65.83 $\pm$ 10.57	2/4	2/4	4	1	0	1




Figure 1. Example of FMFs, its corresponding [18 F]FDG PET image, as well as amyloid PET. Top row: 52-year-old female with suspected lvPPA. (A) Axial slices of [18 F]FDG PET and fusion with CT, showing asymmetric right parieto-temporal hypometabolism. (B) Axial slices of early first-minute [18 F]FMM PET (FMF) and fusion with CT, showing asymmetric right parieto-temporal hypoperfusion with a distribution similar to the corresponding [18 F]FDG PET scan. (C) Axial slice of late-phase [18 F]FMM PET scan, positive for pathological amyloid deposits in the cerebral cortex. The findings support the diagnosis of lvPPA as a presentation of AD with biomarker support. Bottom row: 65-year-old male with focal onset mild to moderate cognitive impairment of the PPA type. (D) Axial slices of [18 F]FDG PET and fusion with CT, showing predominantly left frontal and temporal lobar hypometabolism. (E) Axial slices of early first-minute [18 F]FMM PET (FMF) and fusion with CT, showing frontal and temporal hypoperfusion of similar distribution to the [18 F]FDG PET scan. (F) Axial slice of late-phase [18 F]FMM PET scan, negative for pathological amyloid deposits in the cerebral cortex. The findings support a diagnosis of nvPPA in the context of FTD with biomarker support.

Table 2
Regional SUVRs of FMFs and [18 F]FDG PET grouped by FMF radiotracer.

Brain region		SUVR (Mean $\pm$ SD)								
		Study cohort			18 F]FBP subcohort			18 F]FMM subcohort		
		FMF	18 F]FDG	p-Value	FMF	18 F]FDG	p-Value	FMF	18 F]FDG	p-Value
Frontal	L	0.82 $\pm$ 0.10	0.94 $\pm$ 0.15	<0.001	0.82 $\pm$ 0.10	0.96 $\pm$ 0.16	0.004	0.83 $\pm$ 0.12	0.92 $\pm$ 0.16	0.005
	R	0.89 $\pm$ 0.07	1.02 $\pm$ 0.13	<0.001	0.91 $\pm$ 0.07	1.05 $\pm$ 0.12	<0.001	0.85 $\pm$ 0.07	0.95 $\pm$ 0.12	0.005
Occipital	L	1.09 $\pm$ 0.12	1.25 $\pm$ 0.17	<0.001	1.07 $\pm$ 0.14	1.24 $\pm$ 0.20	<0.001	1.12 $\pm$ 0.10	1.28 $\pm$ 0.13	0.001
	R	1.06 $\pm$ 0.11	1.26 $\pm$ 0.13	<0.001	1.06 $\pm$ 0.13	1.27 $\pm$ 0.15	0.003	1.07 $\pm$ 0.08	1.25 $\pm$ 0.11	<0.001
Parietal	L	0.87 $\pm$ 0.11	1.01 $\pm$ 0.18	<0.001	0.84 $\pm$ 0.11	0.98 $\pm$ 0.21	0.001	0.93 $\pm$ 0.08	1.07 $\pm$ 0.09	<0.001
	R	0.85 $\pm$ 0.10	0.98 $\pm$ 0.14	<0.001	0.84 $\pm$ 0.11	0.98 $\pm$ 0.17	0.003	0.85 $\pm$ 0.07	1.00 $\pm$ 0.08	<0.001
Temporal	L	0.79 $\pm$ 0.09	0.87 $\pm$ 0.14	<0.001	0.76 $\pm$ 0.09	0.84 $\pm$ 0.16	0.003	0.85 $\pm$ 0.06	0.94 $\pm$ 0.09	0.012
	R	0.82 $\pm$ 0.11	0.91 $\pm$ 0.15	<0.001	0.80 $\pm$ 0.12	0.89 $\pm$ 0.17	0.001	0.86 $\pm$ 0.09	0.95 $\pm$ 0.11	0.003
ACC	L	0.85 $\pm$ 0.12	0.94 $\pm$ 0.13	0.001	0.89 $\pm$ 0.08	0.98 $\pm$ 0.10	0.001	0.78 $\pm$ 0.14	0.87 $\pm$ 0.15	0.660
	R	0.86 $\pm$ 0.13	0.97 $\pm$ 0.14	<0.001	0.91 $\pm$ 0.08	1.02 $\pm$ 0.07	<0.001	0.77 $\pm$ 0.16	0.87 $\pm$ 0.18	0.230
PCC	L	0.96 $\pm$ 0.12	1.12 $\pm$ 0.21	<0.001	0.94 $\pm$ 0.12	1.11 $\pm$ 0.25	0.004	1.01 $\pm$ 0.11	1.15 $\pm$ 0.10	0.002
	R	0.85 $\pm$ 0.14	1.03 $\pm$ 0.20	<0.001	0.85 $\pm$ 0.15	1.05 $\pm$ 0.24	<0.001	0.84 $\pm$ 0.14	0.99 $\pm$ 0.10	0.002
Precuneus	L	0.98 $\pm$ 0.14	1.12 $\pm$ 0.23	0.001	0.94 $\pm$ 0.15	1.09 $\pm$ 0.27	0.008	1.06 $\pm$ 0.08	1.18 $\pm$ 0.11	0.001
	R	1.01 $\pm$ 0.15	1.18 $\pm$ 0.23	<0.001	1.00 $\pm$ 0.17	1.18 $\pm$ 0.26	<0.001	1.05 $\pm$ 0.10	1.18 $\pm$ 0.12	<0.001
Striatum	L	0.53 $\pm$ 0.13	0.65 $\pm$ 0.14	<0.001	0.55 $\pm$ 0.10	0.66 $\pm$ 0.13	<0.001	0.50 $\pm$ 0.17	0.64 $\pm$ 0.18	0.002
	R	0.63 $\pm$ 0.15	0.78 $\pm$ 0.16	<0.001	0.65 $\pm$ 0.16	0.81 $\pm$ 0.16	<0.001	0.60 $\pm$ 0.13	0.73 $\pm$ 0.18	0.004

the investigated study cohorts did not focus on patients with PPA in these cases. For example, in early-phase [18 F]FBP PET, Hsiao et al.¹² obtained r values between $r=0.41$ (orbital frontal region) and $r=0.93$ (superior temporal region) for a time window of 0–2 min. Similarly, correlation coefficients reported by Myoraku et al.¹⁵ range between 0.61 and 0.94. Using [18 F]FMM for the early acquisitions (0–10 min), Schmitt et al.¹⁶ obtained correlations to [18 F]FDG PET in cortical regions between $r=0.76$ and $r=0.924$. Boccalini

et al.¹⁷ also showed high correlation coefficients ($r>0.72$) independently of the amyloid PET radiotracer using [18 F]FBP and [18 F]FMM. In the case of early-phase [18 F]FBB, Daerr et al.¹⁹ obtained r values between 0.59 (left frontal and right sensorimotor regions) and 0.86 (right PCC) using a time window of 0–5 min. In this study, FMFs were not acquired with [18 F]FBB but regional correlation coefficients in the study group are generally higher and range between $r=0.84$ (left PCC) and $r=0.97$ (right striatum).

Table 3
Regional SUVRs of FMFs and [¹⁸F]FDG PET grouped by PPA variant.

Brain region		SUVR (Mean ± SD)								
		nfvPPA			lvPPA			Other PPA		
		FMF	[¹⁸ F]FDG	p-Value	FMF	[¹⁸ F]FDG	p-Value	FMF	[¹⁸ F]FDG	p-Value
Frontal	L	0.81 ± 0.11	0.92 ± 0.16	0.001	0.82 ± 0.08	0.96 ± 0.16	0.006	0.85 ± 0.11	0.98 ± 0.22	0.163
	R	0.88 ± 0.10	1.01 ± 0.16	0.001	0.89 ± 0.01	1.05 ± 0.12	0.011	0.89 ± 0.05	1.00 ± 0.13	0.117
Occipital	L	1.12 ± 0.13	1.30 ± 0.18	<0.001	1.07 ± 0.17	1.24 ± 0.20	0.010	1.04 ± 0.05	1.19 ± 0.14	0.042
	R	1.10 ± 0.10	1.31 ± 0.14	<0.001	1.06 ± 0.16	1.27 ± 0.15	0.002	0.98 ± 0.03	1.16 ± 0.06	0.004
Parietal	L	0.89 ± 0.10	1.04 ± 0.15	<0.001	0.87 ± 0.12	0.98 ± 0.21	0.028	0.82 ± 0.13	0.96 ± 0.25	0.173
	R	0.87 ± 0.12	1.02 ± 0.15	<0.001	0.83 ± 0.08	0.98 ± 0.17	0.068	0.81 ± 0.04	0.91 ± 0.12	0.092
Temporal	L	0.83 ± 0.08	0.93 ± 0.12	0.001	0.79 ± 0.12	0.84 ± 0.16	0.186	0.72 ± 0.07	0.78 ± 0.15	0.207
	R	0.86 ± 0.10	0.97 ± 0.13	<0.001	0.83 ± 0.12	0.89 ± 0.17	0.091	0.74 ± 0.10	0.79 ± 0.12	0.169
ACC	L	0.82 ± 0.14	0.91 ± 0.14	0.009	0.90 ± 0.10	0.98 ± 0.10	0.069	0.87 ± 0.08	0.98 ± 0.15	0.110
	R	0.83 ± 0.15	0.93 ± 0.17	0.001	0.91 ± 0.09	1.02 ± 0.07	0.052	0.88 ± 0.09	0.99 ± 0.10	0.127
PCC	L	0.99 ± 0.10	1.16 ± 0.16	0.003	0.96 ± 0.14	1.11 ± 0.25	0.010	0.90 ± 0.16	1.04 ± 0.34	0.287
	R	0.85 ± 0.13	1.07 ± 0.17	<0.001	0.90 ± 0.18	1.05 ± 0.24	0.050	0.78 ± 0.12	0.89 ± 0.20	0.161
Precuneus	L	1.02 ± 0.13	1.17 ± 0.21	0.005	0.95 ± 0.14	1.09 ± 0.27	0.038	0.93 ± 0.18	1.05 ± 0.33	0.226
	R	1.06 ± 0.13	1.24 ± 0.20	0.001	1.00 ± 0.15	1.18 ± 0.26	0.025	0.93 ± 0.16	1.09 ± 0.28	0.089
Striatum	L	0.54 ± 0.16	0.67 ± 0.18	<0.001	0.56 ± 0.09	0.66 ± 0.13	0.068	0.48 ± 0.08	0.60 ± 0.08	0.018
	R	0.67 ± 0.17	0.81 ± 0.18	<0.001	0.67 ± 0.06	0.81 ± 0.16	0.002	0.48 ± 0.08	0.63 ± 0.07	0.004

Table 4
Regional interpatient correlation coefficients of FMF and [¹⁸F]FDG PET. *Statistically significant p-value.

Brain region		Intraclass correlation coefficient r					
		Study cohort	[¹⁸ F]FBP subcohort	[¹⁸ F]FMM subcohort	nfvPPA	lvPPA	Other PPA
Frontal	L	0.91*	0.88*	0.97*	0.95*	0.87	0.85
	R	0.87*	0.82*	0.93*	0.93*	0.20	0.64
Occipital	L	0.93*	0.92*	0.95*	0.92*	0.98*	0.79
	R	0.94*	0.95*	0.94*	0.91*	0.98*	0.75
Parietal	L	0.92*	0.90*	0.97*	0.92*	0.94*	0.89
	R	0.93*	0.92*	0.99*	0.95*	0.93*	0.76
Temporal	L	0.93*	0.92*	0.87*	0.92*	0.94*	0.87
	R	0.95*	0.94*	0.96*	0.95*	0.97*	0.93*
ACC	L	0.90*	0.84*	0.87*	0.91*	0.86	0.82
	R	0.92*	0.70*	0.95*	0.96*	0.73	0.59
PCC	L	0.84*	0.82*	0.92*	0.78*	0.97*	0.79
	R	0.91*	0.92*	0.93*	0.94*	0.92*	0.84
Precuneus	L	0.91*	0.90*	0.95*	0.89*	0.94*	0.91*
	R	0.93*	0.93*	0.97*	0.91*	0.95*	0.92*
Striatum	L	0.94*	0.89*	0.97*	0.96*	0.65	0.90*
	R	0.97*	0.99*	0.94*	0.98*	0.90*	0.93*

In addition to the perfusion-like image of the FMF, this protocol allows acquiring the standard late-phase amyloid PET image of the patient. In the case of PPA, it has been shown that amyloid positivity can help in the classification and identification of the underlying neuropathology. In a systematic review by Villarejo-Galende et al.⁶, the authors found that amyloid positivity was most commonly related to lvPPA (84.9%), while patients with nfvPPA or svPPA rarely exhibited increased amyloid load. In the same way, Bergeron et al.⁷ found a prevalence of amyloid positivity in 86% of cases with lvPPA and only in 20% and 16% for nfvPPA and svPPA, respectively. In the present study group, this distribution can also be observed, where 100% of the lvPPA and ucPPA patients are amyloid positive, while the rest is mainly amyloid negative. The combination of cerebral perfusion and amyloid imaging in one acquisition protocol can therefore improve the diagnosis. Thus, while a positive amyloid PET scan does not imply a diagnosis of AD, in combination with a parieto-temporal hyperperfusion pattern in the FMF it may support a diagnosis of probable AD of patients with lvPPA or svPPA. In the same way, a negative amyloid scan in combination with a frontal hypoperfusion pattern in the case of a patient with nfvPPA may support a diagnosis of FTD. This has also previously been shown by Kuo et al.²¹ where the combination of early and late-phase amyloid PET was able to differentiate healthy controls, AD, and PPA patients.

In this study, one of the main limitations is the reduced study cohort for comparing the two images, while it is in line with previous studies of PPA exclusive cohorts^{4,6,21}. Moreover, only 1 patient was diagnosed with svPPA and for group analyses is grouped with ucPPA patients. In this study, no FMFs were acquired with [¹⁸F]FBB and no healthy control group was available but should be included in future studies with larger sample sizes. Additionally, the visual comparability between FMF and [¹⁸F]FDG PET will be analysed in future studies. Finally, while changes to the cerebral metabolism/perfusion due to neurodegenerative diseases are slow (years), the time difference in the acquisition of FMFs and [¹⁸F]FDG PET images is not equal in all cases (up to 166 days) and might reduce the correlations slightly.

Conclusions

In this study we demonstrated the comparability of the FMF to [¹⁸F]FDG PET in a study cohort of patients diagnosed with different variants of PPA. Quantitative measures and correlation analyses reveal the usefulness of the FMF that this static image of the first minute independently of the amyloid radiotracer is a viable alternative to dynamic early-phase amyloid PET and [¹⁸F]FDG PET imaging. In combination with amyloid PET imaging at the same time it could




Figure 2. Correlation charts with least squares line of the SUVRs of FMFs and $[^{18}\text{F}]\text{FDG}$ PET of the frontal (a: left; b: right), parietal (c: left; d: right), and temporal region (e: left; f: right) of patients with primary progressive aphasia.

be an imaging biomarker for the diagnosis and classification of PPA.

Funding

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Conflict of interest

The authors declare they have no conflict of interest.

Ethical approval

The study complies with the principles of the Helsinki Declaration and was approved by the hospital Ethics and Investigation Committee.

Informed consent

Written informed consent was obtained before image acquisition from the patients.

References

- Mesulam MM. Slowly progressive aphasia without generalized dementia. *Ann Neurol*. 1982;11:592–8.
- Mesulam MM. Current concepts primary progressive aphasia – a language-based dementia. *N Engl J Med*. 2003;349:1535–42.
- Gorno-Tempini ML, Hillis AE, Weintraub S, Kertesz A, Mendez M, Cappa SF, et al. Classification of primary progressive aphasia and its variants. *Neurology*. 2011;76:1006–14.
- Rabinovici GD, Jagust WJ, Furst AJ, Ogar JM, Racine CA, Mormino EC, et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. *Ann Neurol*. 2008;64:388–401.
- Josephs KA, Duffy JR, Fossett TR, Strand EA, Claassen DO, Whitwell JL, et al. Fluorodeoxyglucose F18 positron emission tomography in progressive apraxia of speech and primary progressive aphasia variants. *Arch Neurol*. 2010;67:596–605.
- Villarejo-Galende A, Llamas-Velasco S, Gómez-Grande A, Puertas-Martín V, Contador I, Sarandeses P, et al. Amyloid pet in primary progressive aphasia: case series and systematic review of the literature. *J Neurol*. 2017;264:121–30.
- Bergeron D, Gorno-Tempini ML, Rabinovici GD, Santos-Santos MA, Seeley W, Miller BL, et al. Prevalence of amyloid-β pathology in distinct variants of primary progressive aphasia. *Ann Neurol*. 2018;84:729–40.
- Josephs KA, Martin PR, Botha H, Schwarz CG, Duffy JR, Clark HM, et al. [18F]AV-1451 tau-PET and primary progressive aphasia. *Ann Neurol*. 2018;83:599–611.
- Matías-Guiú JA, Cabrera-Martín MN, Pérez-Castejón MJ, Moreno-Ramos T, Rodríguez-Rey C, García-Ramos R, et al. Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. *Eur J Nucl Med Mol Imaging*. 2015;42:916–27.
- Nestor PJ, Graham NL, Fryer TD, Williams GB, Patterson K, Hodges JR. Progressive non-fluent aphasia is associated with hypometabolism centred on the left anterior insula. *Brain*. 2003;126:2406–18.
- Mummery CJ, Patterson K, Price CJ, Ashburner J, Frackowiak RSJ, Hodges JR. A voxel-based morphometry study of semantic dementia: relationship between temporal lobe atrophy and semantic memory. *Ann Neurol*. 2000;47:36–45.
- Hsiao IT, Huang CC, Hsieh CJ, Hsu WC, Wey SP, Yen TC, et al. Correlation of early-phase 18F-florbetapir (AV-45/Amyvid) PET images to FDG images: preliminary studies. *Eur J Nucl Med Mol Imaging*. 2012;39:613–20.
- Segovia F, Gómez-Río M, Sánchez-Vañó R, Górriz JM, Ramírez J, Triviño-Ibáñez E, et al. Usefulness of dual-point amyloid PET scans in appropriate use criteria: a multicenter study. *J Alzheimer's Dis*. 2018;65:765–79.
- Asghar M, Hinz R, Herholz K, Carter SF, Carter SF. Dual-phase [18F] florbetapir in frontotemporal dementia. *Eur J Nucl Med Mol Imaging*. 2019;46:304–11.
- Myoraku A, Klein G, Landau S, Tosun D. Regional uptakes from early-frame amyloid PET and 18F-FDG PET scans are comparable independent of disease state. *Eur J Hybrid Imaging*. 2022;6:1–14.
- Schmitt J, Palleis C, Sauerbeck J, Unterrainer M, Harris S, Prix C, et al. Dual-phase β-amyloid PET captures neuronal injury and amyloidosis in corticobasal syndrome. *Front Aging Neurosci*. 2021;13(661284).
- Boccalini C, Peretti DE, Ribaldi F, Scheffler M, Stampacchia S, Tomczyk S, et al. Early-phase 18 F-florbetapir and 18 F-flutemetamol images as proxies of brain metabolism in a memory clinic setting. *J Nucl Med*. 2022;ijnmed.122.264256.
- Tiepol S, Hesse S, Patt M, Luthardt J, Schroeter ML, Hoffmann KT, et al. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease. *Eur J Nucl Med Mol Imaging*. 2016;43:1700–9.
- Daerr S, Brendel M, Zach C, Mille E, Schilling D, Zacherl MJ, et al. Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases. *NeuroImage Clin*. 2017;14:77–86.
- Son SH, Kang K, Ko PW, Lee HW, Lee SW, Ahn BC, et al. Early-phase 18F-florbetaben PET as an alternative modality for 18F-FDG PET. *Clin Nucl Med*. 2020;45:e8–14.
- Kuo HC, Hsiao IT, Hsieh CJ, Huang CY, Huang KL, Wai YY, et al. Dual-phase 18F-florbetapir positron emission tomography in patients with primary progressive aphasia, Alzheimer's disease, and healthy controls: a preliminary study. *J Formos Med Assoc*. 2017;116:964–72.
- Seiffert AP, Gómez-Grande A, Villarejo-Galende A, González-Sánchez M, Bueno H, Gómez EJ, et al. High correlation of static first-minute-frame (FMF) PET imaging after 18F-labeled amyloid tracer injection with [18F]FDG PET imaging. *Sensors*. 2021;21:5182.
- Friston KJ, Ashburner J, Kiebel S, Nichols T, Penny WD. Statistical parametric mapping: the analysis of functional brain images. 1st ed. London, UK: Elsevier/Academic Press; 2006. 656 p.
- Presotto L, Iaccarino L, Sala A, Vanoli EG, Muscio C, Nigri A, et al. Low-dose CT for the spatial normalization of PET images: a validation procedure for amyloid-PET semi-quantification. *NeuroImage Clin*. 2018;20:153–60.
- Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. *Neuroimage*. 2002;15:273–89.
- Rolls ET, Joliet M, Tzourio-Mazoyer N. Implementation of a new parcellation of the orbitofrontal cortex in the automated anatomical labeling atlas. *Neuroimage*. 2015;122:1–5.
- Matías-Guiú JA, Díaz-Álvarez J, Ayala JL, Risco-Martín JL, Moreno-Ramos T, Pytel V, et al. Clustering analysis of FDG-PET imaging in primary progressive aphasia. *Front Aging Neurosci*. 2018;10(230):1–12.
- Grossman M. Primary progressive aphasia: clinicopathological correlations. *Nat Rev Neurol*. 2010;6:88–97.
- Montembeault M, Brambati SM, Gorno-Tempini ML, Migliaccio R. Clinical, anatomical, and pathological features in the three variants of primary progressive aphasia: a review. *Front Neurol*. 2018;9:1–16.